NEW YORK – Lifebit Biotech said this week that it has closed a Series B funding round worth $60 million.
Tiger Global Management led the round, with participation from previous investors Eurazeo, Pentech Ventures, and Beacon Capital.
London-based Lifebit is a biomedical software firm that makes CloudOS, a cloud-native, federated genomics operating system for precision medicine. CloudOS functions as a managed service of individual clouds or high-performance computing centers to support analysis of bioinformatics data across sites and institutions.
In a statement, Lifebit CEO Maria Chatzou Dunford said that the company would use the new funding to expand its global presence and expand its workforce.
"We are confident that Lifebit's innovative … software solutions, paired with their customer-first approach, will drive rapid global adoption and accelerate breakthroughs in precision medicine," added John Curtius, partner at Tiger Global.
Lifebit closed a £6 million ($8.1 million) Series A funding round in April 2020.